title: Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration.
abstract: Calcineurin inhibitors such as cyclosporine A (CsA) are still commonly used after renal transplantation, despite CsA--induced nephrotoxicity (CIN), which is partly related to vasoactive mechanisms. The mineralocorticoid receptor (MR) is now recognized as a key player in the control of vascular tone, and both endothelial cell- and vascular smooth muscle cell (SMC)-MR modulate the vasoactive responses to vasodilators and vasoconstrictors. Here we tested whether vascular MR is involved in renal hemodynamic changes induced by CsA. The relative contribution of vascular MR in acute CsA treatment was evaluated using mouse models with targeted deletion of MR in endothelial cell or SMC. Results indicate that MR expressed in SMC, but not in endothelium, contributes to the increase of plasma urea and creatinine, the appearance of isometric tubular vacuolization, and overexpression of a kidney injury biomarker (neutrophil gelatinase--associated lipocalin) after CsA treatment. Inactivation of MR in SMC blunted CsA--induced phosphorylation of contractile proteins. Finally, the in vivo increase of renal vascular resistance induced by CsA was blunted when MR was deleted from SMC cells, and this was associated with decreased L-type Ca2D channel activity. Thus, our study provides new insights into the role of vascular MR in renal hemodynamics during acute CIN, and provides rationale for clinical studies of MR antagonism to manage the side effects of calcineurin inhibitors.
authors.forename: Cristian A
authors.initials: CA
authors.lastname: Amador
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Bertocchio
authors.forename: Gwennan
authors.initials: G
authors.lastname: Andre-Gregoire
authors.forename: Sandrine
authors.initials: S
authors.lastname: Placier
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Duong Van Huyen
authors.forename: Soumaya
authors.initials: S
authors.lastname: El Moghrabi
authors.forename: Stefan
authors.initials: S
authors.lastname: Berger
authors.forename: David G
authors.initials: DG
authors.lastname: Warnock
authors.forename: Christos
authors.initials: C
authors.lastname: Chatziantoniou
authors.forename: Iris Z
authors.initials: IZ
authors.lastname: Jaffe
authors.forename: Philippe
authors.initials: P
authors.lastname: Rieu
authors.forename: Frederic
authors.initials: F
authors.lastname: Jaisser
mesh_terms: D000818:Animals; D020746:Calcium Channels, L-Type / Q000378:metabolism; D016572:Cyclosporine / Q000009:adverse effects*; D004730:Endothelium, Vascular / Q000378:metabolism; D005260:Female; D055786:Gene Knockout Techniques; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007674:Kidney Diseases / Q000209:etiology* / Q000378:metabolism; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009131:Muscle, Smooth, Vascular / Q000378:metabolism; D018161:Receptors, Mineralocorticoid / Q000378:metabolism*; D014655:Vascular Resistance
chemical_list: D020746:Calcium Channels, L-Type; D007166:Immunosuppressive Agents; D018161:Receptors, Mineralocorticoid; D016572:Cyclosporine